Related Experiment Video

Updated: Jun 27, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.4K

Long non-coding RNA LOXL1-AS1: a potential biomarker and therapeutic target in human malignant tumors

Xiao-Ping Fu1, Chun-Yan Ji2, Wen-Qian Tang1

  • 1Department of Health Management Center, Hubei Provincial Hospital of Traditional Chinese Medicine, Hongshan District, 856 Luoyu Road, Wuhan, 430070, People's Republic of China.

Clinical and Experimental Medicine
|May 1, 2024
PubMed

Insights

Long non-coding RNA LOXL1-AS1 plays a key role in various human cancers by regulating cell processes and signaling pathways. This lncRNA shows promise as a cancer biomarker and therapeutic target.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • Long non-coding RNAs (lncRNAs) are critical regulators in human cancers, despite not coding for proteins.
  • Lysyl oxidase like 1 antisense RNA 1 (LOXL1-AS1) is a newly identified lncRNA implicated in multiple cancer types.

Purpose of the Study:

  • To review the biological functions and clinical significance of LOXL1-AS1 in human malignancies.
  • To explore LOXL1-AS1's potential as a cancer biomarker and therapeutic target.

Main Methods:

  • Literature review of studies investigating LOXL1-AS1 in various cancers.
  • Analysis of LOXL1-AS1's mechanisms, including its role as a competing endogenous RNA (ceRNA) sponging miRNAs.
  • Examination of LOXL1-AS1's involvement in cancer-related signaling pathways (e.g., PI3K/AKT, MAPK) and cellular processes.

Main Results:

  • LOXL1-AS1 is dysregulated in numerous cancers, including colorectal, gastric, liver, prostate, lung, ovarian, cervical, breast, glioma, thymic, and pancreatic cancers.
  • LOXL1-AS1 promotes tumor progression by sponging various microRNAs (miRNAs), influencing cell proliferation, invasion, migration, apoptosis, cell cycle, and epithelial-mesenchymal transition (EMT).
  • LOXL1-AS1 impacts key cancer signaling pathways like PI3K/AKT and MAPK.

Conclusions:

  • LOXL1-AS1 is a significant player in the development and progression of diverse human cancers.
  • LOXL1-AS1's multifaceted roles suggest its potential as a reliable diagnostic biomarker and a promising therapeutic target for cancer treatment.
Keywords:
BiomarkerCancerLOXL1-AS1Long non-coding RNATherapeutic target

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

280
Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool08:49

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

11.1K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K